Back to top
more

Nurix Therapeutics (NRIX)

(Real Time Quote from BATS)

$11.42 USD

11.42
151,957

+0.14 (1.24%)

Updated Aug 5, 2025 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beyond Air (XAIR) delivered earnings and revenue surprises of 35.71% and 17.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?

by Zacks Equity Research

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 6.94% and 26.41%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

by Zacks Equity Research

Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of -42.86% and 51.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 9.09% and 23.72%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -11.94% and 22.55%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 0% and 9.11%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%

by Zacks Equity Research

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice

by Zacks Equity Research

Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -7.58% and 37.51%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

by Zacks Equity Research

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

Zacks Equity Research

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

by Zacks Equity Research

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Zacks Equity Research

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

by Zacks Equity Research

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.